橫幅
News
16
2026.04
The Company announces that its subsidiary,Tulex Pharmaceuticals, has submitted an NDA for TLX-042 (505(b)(2)) to the U.S. FDA.
The Company announces that its subsidiary,Tulex Pharmaceuticals, has submitted an NDA for TLX-042 (505(b)(2)) to the U.S. FDA.
more
16
2026.03
敬致全體股東：關於易威生醫科技股份有限公司與健亞生物科技股份有限公司日前公告之股份交換合作案說明
more
12
2026.03
易威生醫宣布以股份轉換方式併購健亞生技
more
01
2026.03
代子公司美國Tulex Pharmaceuticals公告,共同開發新藥(505(b)(2))液態口服治療尿崩症藥品,接獲美國FDA通知領取藥證
more
18
2025.11
Tulex Pharmaceuticals and Artisan Therapeutics Announce Positive Phase 2a Results for ARD-501, a Novel Oral Liquid Extended-Release Formulation for Autism Spectrum Disorder
more